Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192763 · ClinicalTrials.gov registry record · Phase 1
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01192763: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01192763 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01192763, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects of RO4929097 before surgery in treating patients with pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth. Giving RO4929097 before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE therapeutic conventional surgery
- OTHER pharmacological study
- DRUG gamma-secretase/Notch signalling pathway inhibitor RO4929097
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01192763
The ClinicalTrials.gov registry entry for NCT01192763 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01192763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01192763 about?
NCT01192763 is a clinical study titled "RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer". This phase I trial is studying the side effects of RO4929097 before surgery in treating patients with pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth. Giving RO4929097 before surgery may make the tumor smaller and reduce the amount of n...
What is the current status of trial NCT01192763?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-08.
What interventions are being tested in trial NCT01192763?
The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic conventional surgery (PROCEDURE), pharmacological study (OTHER), gamma-secretase/Notch signalling pathway inhibitor RO4929097 (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT01192763?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.